Comparing ICANS vs CRS in CAR T Cell Therapy

A fever spikes at 39.8°C three days after infusion and the team must decide within minutes which syndrome is unfolding, since the first-line drug differs between the two. Cytokine release syndrome (CRS) is a systemic inflammatory injury that typically strikes within the first week of infusion, while immune effector cell-associated neurotoxicity syndrome (ICANS) is a localized brain injury driven by endothelial activation and cytokine diffusion across the blood-brain barrier, most often surfacing between days five and ten. Both share the same upstream trigger, a cytokine surge from in vivo CAR T-cell expansion, yet they target different organs and demand different treatments, which is why confusing the two can cost hours of clinical decision-making.

Below, you’ll see how the two syndromes diverge in onset, severity grading, and first-line therapy, and where bedside errors tend to happen. The focus is practical: signs to watch for, the grading framework that separates them, and how clinicians choose between tocilizumab and steroids when both syndromes collide.

The Shared Biology Behind Two Distinct Toxicities

CAR T-cell expansion after infusion drives a cytokine surge that threatens both the bloodstream and the central nervous system at the same time. Once the engineered T cells encounter antigen and proliferate, they release IL-6, IFN-gamma, TNF-alpha, and GM-CSF in quantities that overflow normal immune regulation. CRS reflects the systemic spill of those messengers, while ICANS reflects the localized neurotoxicity that follows once cytokines cross, or disrupt, the blood-brain barrier.

Both syndromes typically emerge within the first two weeks and frequently co-occur, which complicates the bedside picture. A patient who appears to be recovering from fever and hypotension can quietly drift into confusion, tremor, or aphasia as systemic inflammation wanes. Shared upstream triggers explain why prevention strategies overlap:

• ▸High baseline tumor burden amplifies antigen-driven expansion and the cytokine load that follows.
• ▸Intensive lymphodepletion (typically fludarabine plus cyclophosphamide) creates a cytokine-friendly niche.
• ▸Rapid in vivo T-cell expansion correlates with both peak IL-6 levels and the risk of severe neurotoxicity.
• ▸Product-specific CAR construct design influences which patients tip into ICANS even after CRS resolves.

The mechanistic overlap is exactly what makes the two syndromes hard to disentangle, and it is the reason a side-by-side comparison matters more than a sequential summary.

Why one cytokine pathway produces two syndromes

Endothelial activation is the hinge. IL-6 and other inflammatory mediators disrupt the blood-brain barrier, allowing cytokines and possibly the CAR T cells themselves to enter the CNS compartment. That crossover explains why ICANS almost always trails CRS by a few days rather than appearing in isolation.

How CRS Presents and Why It Differs From ICANS

CRS manifests as fever, hypotension, hypoxia, and organ dysfunction tied to elevated IL-6, ferritin, and CRP. The clinical signature is hemodynamic and respiratory, not neurologic. By contrast, ICANS presents with expressive aphasia, tremor, dysgraphia, impaired attention, somnolence, and, in severe cases, seizures or cerebral edema, with relatively preserved vitals early on.

Onset typically falls between days 1 and 14, with median onset around days 2 to 5 for most CD19-directed products such as tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), and lisocabtagene maraleucel (Breyanzi). ICANS frequently follows CRS onset or develops concurrently, with a slightly delayed median timeline.

“Bedside reality: the temporal overlap means ICANS can be masked until CRS begins to resolve, because attention is drawn to fevers and blood pressure first.

A practical bedside timeline

1. 1Days 0–1: Low-grade fever may begin; CRP starts to rise.
2. 2Days 2–5: Peak CRS risk for most CD19 constructs; watch hypotension and oxygen requirement.
3. 3Days 5–10: ICANS window opens, especially in patients whose CRS was severe or prolonged.
4. 4Days 10–14: Most syndromes have declared themselves; persistent symptoms warrant reassessment for HLH/MAS or alternative diagnoses.

Grading Frameworks That Separate Severity Tiers

The 2018 ASTCT (American Society for Transplantation and Cellular Therapy) consensus criteria unified grading for both CRS and ICANS, replacing the older Lee scale and CTCAE versions. The unified framework lets a single team speak the same language when escalating care, which matters because institutions often inherit inconsistent documentation from earlier trials.

Product-specific incidence rates vary: grade ≥3 CRS occurs in roughly 10 to 30% of recipients across the major CD19 constructs, while any-grade ICANS ranges from 20 to 60% depending on the CAR construct and disease setting. BCMA-directed therapies can carry ICANS rates near the higher end, particularly in patients with high marrow disease burden.

Why unified grading changed the conversation

Before ASTCT 2018, trial reports used different CRS definitions, which made cross-product comparisons almost meaningless. The unified criteria let clinicians compare axicabtagene ciloleucel and lisocabtagene maraleucel on the same scale and accelerated regulatory dialogue with the FDA on toxicity labeling.

That common scale, however, only matters once clinicians know which intervention matches each tier.

Choosing Between Tocilizumab, Steroids, and Adjunctive Agents

Tocilizumab is first-line for CRS because it blocks IL-6 receptor signaling and rapidly reverses fever and hypotension. Its large molecular weight means it penetrates the blood-brain barrier poorly, so it does little for neurotoxicity once the syndrome has crossed into the CNS.

Corticosteroids such as dexamethasone or methylprednisolone are preferred for ICANS because they cross into the CNS and reduce neuroinflammation directly. Most ICANS algorithms call for steroids at grade 2 or higher, while reserving tocilizumab for concurrent or worsening CRS.

Stepwise escalation by syndrome

• ▸CRS grade 1–2: Supportive care, antipyretics, and tocilizumab 8 mg/kg IV if no rapid improvement.
• ▸CRS grade 3–4: Tocilizumab plus ICU admission, vasopressors, and consideration of steroids if ICANS co-exists.
• ▸ICANS grade 1: Close neuro checks; consider dexamethasone 10 mg IV.
• ▸ICANS grade 2–3: Dexamethasone 10 mg IV every 6 hours, ICU admission, neurology consult, neuroimaging.
• ▸ICANS grade 4 or refractory: High-dose methylprednisolone, seizure management, consideration of anakinra (IL-1 receptor antagonist) for refractory or overlapping syndromes.

“Tip: Anakinra is increasingly studied for refractory or overlapping syndromes, particularly when hemophagocytic lymphohistiocytosis-like features are present, and several centers use it off-label as a steroid-sparing bridge.

Predicting Who Develops Each Toxicity

High baseline tumor burden, elevated ferritin, and intensive lymphodepletion predict both CRS and ICANS risk. Pre-infusion disease volume is one of the most reproducible signals across CD19 products, and it tracks with peak cytokine exposure once the CAR T cells engage.

Product-specific factors matter: axi-cel (axicabtagene ciloleucel) and some BCMA-directed therapies carry higher ICANS rates than tisagenlecleucel. Lisocabtagene maraleucel has a defined CD4:CD8 composition that appears to lower severe CRS rates relative to early-generation constructs, while brexucabtagene autoleucel in mantle cell lymphoma carries a notable ICANS burden.

Early warning signals worth tracking

• ▸CRP trajectory: CRP rising above 100 mg/L in the first 72 hours often precedes severe CRS.
• ▸Ferritin and LDH baseline: Markedly elevated baseline ferritin flags higher-grade toxicity risk.
• ▸Cytokine panels: Sharp rises in IL-6, IFN-gamma, and TNF-alpha within the first three days precede severe syndromes.
• ▸Neuroimaging baselines: Preexisting CNS disease, prior whole-brain radiation, or active CNS involvement raises ICANS vulnerability independently of systemic inflammation.

For example, a patient with refractory diffuse large B-cell lymphoma and a baseline ferritin above 2,000 ng/mL who receives axi-cel is at meaningfully higher risk of both grade ≥3 CRS and ICANS than a low-burden indolent NHL recipient, and that risk profile should drive prophylactic monitoring intensity rather than reactive escalation.

Clinical Decision Points and Pitfalls in Daily Practice

Concurrent CRS and ICANS require treating the more life-threatening component first, usually severe CRS with hemodynamic instability, because perfusion failure accelerates neurologic injury. Once the patient is hemodynamically stable, steroids can be layered for the neurologic component without compromising CRS control.

Failure to recognize ICANS behind resolving CRS symptoms is the most common bedside error. Fever improves, blood pressure normalizes, and the team relaxes, only to miss a patient whose writing sample or attention testing has quietly worsened. Twice-daily ICE scoring during the risk window catches this drift before grade 3 or 4 ICANS sets in.

Common pitfalls and how to avoid them

• ▸Re-dosing tocilizumab alone for neurologic deterioration delays effective steroid therapy and allows neurotoxicity to escalate.
• ▸Assuming sedation masks encephalopathy in intubated patients; rely on imaging, EEG, and pupillary findings instead.
• ▸Skipping seizure prophylaxis in grade ≥2 ICANS; levetiracetam is standard at most centers.
• ▸Forgetting B-cell aplasia follow-up once toxicity resolves; hypogammaglobulinemia and infection risk persist for months.

“Warning: Institutional protocols that bundle ASTCT-based monitoring, premedication adjustments, and ICU escalation pathways reduce treatment discordance between syndromes and shorten time-to-steroid for ICANS.

For instance, a treatment center that mandates ICE scoring every 8 hours from day 3 through day 14, automatic neurology consult at ICE ≤7, and pre-positioned dexamethasone on the infusion floor will typically halve the time from neurologic symptom onset to first steroid dose compared with centers that rely on ad hoc escalation.

Bottom Line

CRS and ICANS share a cytokine-driven origin but diverge sharply in target organ, timing, and treatment. Tocilizumab resolves systemic inflammation while steroids reach the CNS compartment where ICANS lives. Recognizing the temporal lag, grading with the ASTCT framework, and escalating the more life-threatening syndrome first are the three moves that separate clean recoveries from prolonged ICU stays.

FAQ